Providence Biotherapy Program is the only program in Oregon offering high-dose interleukin-2 (IL-2) immunotherapy
to patients with metastatic kidney cancer and metastatic melanoma. Interleukin-2 immunotherapy is an FDA-approved treatment that stimulates a patient’s own immune system to better target and destroy cancer cells.
Providence Biotherapy Program is part of the Robert W. Franz Cancer Research Center
in the Earle A. Chiles Research Institute at Providence Cancer Center on the campus of Providence Portland Medical Center. We are among the busiest high-dose IL-2 centers in the nation, with more than 130 patients admitted for this therapy every year.
In addition to providing high-dose IL-2 treatment, we offer innovative clinical research trials. Clinical trials
available to patients may include cancer vaccines, novel chemotherapy approaches and new medicines to stimulate the immune system, including cell-based and cytokine-based immunotherapy medicines. We provide personal service and support to cancer patients in the state-of-the-art Providence Cancer Center on the campus of Providence Portland Medical Center.